Drug discovery in Alzheimer’s disease using metal chelators: Warning toward their usage

研究成果: 書籍/レポート タイプへの寄稿

抄録

Alzheimer’s disease (AD) is a devastating neurodegenerative dementia exhibiting abnormal protein aggregations of amyloid β and tau proteins in the brain. Although its detailed molecular mechanism remains unclear, accumulating evidences have suggested that autophagy is impaired in AD patients. Autophagy is a fundamental degradation process to clear unnecessary and even pathological substances in the cells, functioning a key cellular process for homeostasis. Recent attempts employing metal chelators such as clioquinol for the treatment of AD have been made because Aβ and tau protein can bind to metal ions such as copper and zinc and their contents are known to be abnormal in AD. By chelating these metals with chelators, protein aggregates can be dissolved resulting in the clearance of aggregated proteins. Recent studies, however, have suggested that clioquinol can induce autophagy and can cause autophagy-related cell death depending on its concentration. Therefore, we should be very careful for its concentration in vivo when it is used for the treatment of AD.

本文言語英語
ホスト出版物のタイトルAutophagy Dysfunction in Alzheimer's Disease and Dementia
出版社Elsevier
ページ291-303
ページ数13
ISBN(電子版)9780323899062
ISBN(印刷版)9780323899147
DOI
出版ステータス出版済み - 01-01-2022

All Science Journal Classification (ASJC) codes

  • 医学一般
  • 神経科学一般

フィンガープリント

「Drug discovery in Alzheimer’s disease using metal chelators: Warning toward their usage」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル